SCHEMBL24928346

SCHEMBL24928346

CC(C)CCC(=O)CNC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
GAA P10253 1/20 0.46
TDP1 Q9NUW8 1/20 0.41
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
KCNA5 P22460 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
CTSK P43235 6/20 0.39
CTSS P25774 3/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CAPN1 P07384 1/20 0.37
CYP2D6 P10635 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10521561 0.84 MEN1 (0.33) MEN1KMT2AGAACA1KCNA5
SCHEMBL21582671 0.84 MEN1 (0.39) MEN1KMT2AGAATDP1CA1
SCHEMBL4714065 0.81 TDP1 (0.52) MEN1KMT2AGAATDP1CA1
SCHEMBL8535486 0.80 TDP1 (0.53) MEN1KMT2AGAATDP1CA1
SCHEMBL3686909 0.80 TDP1 (0.44) MEN1KMT2AGAATDP1CA1
SCHEMBL4478336 0.79 MEN1 (0.45) MEN1KMT2AGAATDP1CA1
SCHEMBL10924213 0.79 MEN1 (0.40) MEN1KMT2AGAATDP1CA1
SCHEMBL12880622 0.78 MEN1 (0.43) MEN1KMT2AGAATDP1CA1
SCHEMBL397759 0.78 MEN1 (0.61) MEN1KMT2AGAATDP1CA1
SCHEMBL16742485 0.78 MEN1 (0.53) MEN1KMT2AGAATDP1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists BAYER AKTIENGESELLSCHAFT (DE) 2025-08-26 US disclosed
EP-4058448-B1 HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER AG (DE) 2024-05-29 EP disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-4058448-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists ADAMTS7, MMP7, ADAM17 MEN1 2481/4885KMT2A 3535/4885GAA 2633/4885
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAM17 MEN1 2481/4885KMT2A 3535/4885GAA 2633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.